Too Old to Operate14m
Neoadjuvant SHR-A1811 Shows Promise in Fighting HER2-Positive Breast Cancer
Neoadjuvant SHR-A1811 showed similar pathologic complete response rates to the standard 4-drug regimen in patients with ...
Too Old to Operate58m
Margetuximab Does Not Improve pCR Rate in HER2-Positive Early Breast Cancer
The MARGOT/TBCRC052 trial didn't show improvement in pathologic complete response rates with margetuximab for early-stage HER2-positive breast cancer.